JAK inhibitor in CALR-mutant myelofibrosis

New England Journal of Medicine

Volumn 370, Issue 12, 2014, Pages 1168-1169

  Passamonti, Francesco ^a   Caramazza, Domenica ^a   Maffioli, Margherita ^a  

^a OSPEDALE DI CIRCOLO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; FEDRATINIB; JANUS KINASE 2; JANUS KINASE INHIBITOR; MUTANT PROTEIN; STAT PROTEIN;

ADULT; AGED; CASE REPORT; CELL GROWTH; CELL LINE; DNA SEQUENCE; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; EXON; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; GENETIC VARIABILITY; HUMAN; LETTER; MALE; MEDICAL DECISION MAKING; MYELOID METAPLASIA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLEEN SIZE;

CALRETICULIN; HUMANS; MUTATION; MYELODYSPLASTIC SYNDROMES; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84896480418     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1400499     Document Type: Letter

References (5)

1. Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013;122:4047-53.
2. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011;29:789-96.
3. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369:2379-90.
4. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369:2391-405.
5. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010;115:1703-8.